Adicet Expands CAR-T Portfolio With Cleared ADI-212 IND and In-Vivo Programs

Company: Adicet Bio · Asset: ADI-212 (Gamma-Delta CAR-T) · Indication: Metastatic Castration-Resistant Prostate Cancer · Platform: In-Vivo CAR-T (Multiple Programs) · Date: September 1, 2026 Summary Adicet disclosed FDA clearance of the ADI-212 IND for metastatic castration-resistant prostate cancer and unveiled an in-vivo CAR-T portfolio…